Survodutide
A weekly dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma for obesity and MASH.
Overview
Survodutide is a dual GLP-1 / glucagon receptor agonist designed for once-weekly subcutaneous administration. It has shown strong weight-loss outcomes in obesity trials and is also being investigated for metabolic dysfunction-associated steatohepatitis (MASH).
Benefits
- Strong weight loss in trials
- Improved metabolic markers
- Dual mechanism leverages glucagon-driven energy expenditure
- Also studied for liver health in MASH
Mechanism of Action
Activates both GLP-1 and glucagon receptors. GLP-1 controls appetite and improves insulin response, while glucagon increases lipolysis, energy expenditure, and supports fatty-liver resolution.
Dosage (informational only)
- Typical range
- Up to 6 mg per week (trial range)
- Frequency
- Weekly subcutaneous administration
Currently investigational. Approval pathways underway for obesity and MASH.
Side Effects
- Nausea and vomiting
- Diarrhea
- Decreased appetite
- Possible elevated heart rate
Related peptides
A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.
A dual GIP and GLP-1 receptor agonist with strong effects on appetite, glucose handling, and body composition.
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing some of the largest weight-loss results recorded in trials.